Relay Therapeutics’ stock {$RLAY} rose about 6% on Wednesday morning after it released positive interim data for its PI3Kα inhibitor in breast cancer.
In the Phase 1/2 trial, 64 patients with second-line PI3Kα-mutated, HR+, HER2 ...
↧